Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SustainedRelease to 10 mg Donepezil Immediate Release in Patients with Moderate toSevere Alzheimer’s Disease - E2020-G000-326

Eisai Ltd0 个研究点目标入组 1,200 人开始时间: 2007年8月8日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 1,200

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Inclusion Criteria for Patients
•6) Stable Aricept® dose of 10 mg IR (or 10 mg dose of generic donepezil bioequivalent to Aricept®), taken as a single, daily dose for = 3 months prior to the Screening visit. Tablets must not be broken or crushed. Any patient who splits daily doses (for example, Aricept® taken as two daily 5 mg doses instead of a single 10 mg dose) will not be enrolled in the study. (Revised per Amendment 02)
•7) Cranial image: no evidence of focal disease to account for dementia on any cranial image (MRI or CT) obtained within 12 months prior to Baseline (Revised per Amendment 02). If no cranial image (MRI or CT) obtained within 12 months prior to Baseline is available, an attempt should be made to obtain the cranial image with contrast (CT and MRI), unless the use of contrast is clinically contra-indicated. (Added per Amendment 03)
•8) Degree of dementia: MMSE score 1 to 20 at Screening and Baseline (Revised per
•Amendment 04)
•10) SIB = 90 at both Screening and Baseline (Re-numbered as per Amendment 02). Patients will be allowed to re-screen at a later time if their SIB scores are borderline (after 3 months if these scores are 91 or 92, or after 6 months if these scores are 93 or 94) (revised per Amendment 04). At re-screening a new patient ID number will be assigned to these patients, and all screening assessments will be repeated. (Added per Amendment 03)
•13) Specified doses of SSRIs are allowed in the study. Patients undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) at doses that are less than or equal to the approved dose range of therapeutic efficacy as specified in the Physician’s Desk Reference or regional equivalent may enter the study provided that the SSRI dose has been stable for at least 3 months prior to Screening. (Added per Amendment 03)
•14) Co-morbid medical conditions must be well-controlled and the patient maintained on stable doses of medications for 3 months. Patients with risk factors of hypertension and cardiac disease may be enrolled in the study, provided that hypertension is well controlled by medication in the clinical judgment of the investigator (supine diastolic BP < 95 mm Hg) and cardiac disease (e.g. angina pectoris, congestive heart failure, or right bundle branch block) is stable on appropriate medication for 3 months prior to Screening. Peripheral vascular disease must have been stable for 3 months prior to Screening. (Revised per Amendments 03 and 04)
•16) Patients whose serum B12 levels at Screening are below the normal range may
•nonetheless be admitted to the study if they subsequently show normal levels prior to Baseline. Patients who are receiving Vitamin B12 supplements should maintain a stable dose/regimen throughout the study. (Revised per Amendments 03 and 04)
•18) Concomitant Medications: Patients undergoing treatment with the following medications may be enrolled in the study provided these conditions are met:
•a. Chronic daily benzodiazepine use may be allowed if doses are stable within
•approved dose range consistent with currently accepted standards of practice for at
•least 1 year prior to screening, to be confirmed by Medical Monitor. Chronic
•intermittent use of benzodiazepines may be allowed pending consultation and
•approval by the Medical Monitor but not within 48 hours of scheduled assessment.
•b. Bronchodilator medications for treatment of COPD may be allowed as long as
•drug is administered via metered dose inhaler within approved dose range.

排除标准

•Exclusion Criteria for Patients
•1) Patients taking (a) no medication for Alzheimer’s disease, (b) Aricept® or bioequivalent generic donepezil at doses other than 10 mg daily, or 10 mg for
•< 3 months before Screening; (c) other medications for Alzheimer’s disease, with the
•following exceptions (Revised per Amendment 02):
•a. Memantine is allowed if taken at prescribed doses that are less than or equal to
•20 mg/day, provided that the dose has been stable for at least 3 months prior to
•Screening (Revised per Amendments 03 and 04)
•b. Vitamin E and/or fish oil and/or gingko biloba are allowed if the dose(s) have
•been stable for at least 3 months prior to the Screening visit, provided that
•doses are not changed during the study (revised per Amendment 04).
•3) Patients who have no measurable concentrations of donepezil in blood samples
•collected at Screening (Corrected per Amendment 02)
•5) Patients with psychiatric disorders affecting the ability to assess cognition such as
•schizophrenia, bipolar or unipolar depression. Patients with clinically significant
•sleep disorders will also be excluded unless these are controlled by treatment and
•clinically stable for > 3 months prior to screening (Revised per Amendment 01).
•6) Patients with dementia complicated by other organic disease or Alzheimer’s disease with delirium (DSM IV 290.30 or 290.11; Appendix 5)
•7) Patients with drug or alcohol abuse or dependence within the past 5 years according to DSM IV criteria (Appendix 5)
•8) Patients with any active or clinically significant conditions affecting absorption,
•distribution, or metabolism of the study medication (eg, inflammatory bowel disease,
•gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance)
•9) Patients with evidence of clinically significant, active gastrointestinal, renal, hepatic, respiratory, endocrine, or cardiovascular system disease (Revised per Amendment 02)
•10) Patients with a history of malignant neoplasms (does not include basal or squamous cell carcinoma of the skin) treated within 5 years prior to study entry, current evidence of malignant neoplasm, recurrent, metastatic disease. Males with localized prostate cancer requiring no treatment would not be excluded.
•12) Donation of blood or blood products during 30 days prior to Screening or plans to
•donate blood while participating in the study or within 30 days after completion of the study
•13) Patients who are unwilling or unable to fulfill the requirements of the study
•14) Known hypersensitivity to acetylcholinesterase inhibitors or memantine (Revised per Amendment 01)
•15) Use of any prohibited prior or concomitant medications as described in Section 10.7 and listed in Appendix 4
•16) Any condition that would make the patient, in the opinion of the investigator,
•unsuitable for the study
•17) Involvement in any other investigational drug clinical trial during the preceding
•3 months, or likely involvement in any other such trial during the course of this study
•18) Patients taking concomitant antidepressant medication known to have significant
•anticholinergic effects, such as tricyclic antidepressants prescribed at doses recommended for the treatment of major depression. Prohibited antidepressants are
•listed in Appendix 4. (Added per Amendment 02)
•19) Patients who cannot swallow or who have difficult swallowing whole tablets. (Added per Amendment 02)
•20) Patients with fecal and/or urinary incontinence who are unable to cooperate with
•routine specime

研究者

发起方

Eisai Ltd

相似试验

进行中（未招募）

1 期

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SustainedRelease to 10 mg Donepezil Immediate Release in Patients with Moderate toSevere Alzheimer’s Disease - E2020-G000-326Alzheimer's Disease

EUCTR2006-004888-54-GBEisai Ltd1,200

进行中（未招募）

不适用

EUCTR2006-004888-54-DKEisai Ltd1,200

进行中（未招募）

不适用

EUCTR2006-004888-54-SEEisai Ltd1,200

进行中（未招募）

不适用

EUCTR2006-004888-54-LTEisai Ltd1,200

进行中（未招募）

不适用

EUCTR2006-004888-54-DEEisai Ltd1,200